New combo therapy for advanced breast cancer shows promise in early trial
NCT ID NCT06570031
First seen Jun 09, 2026 · Last updated Jun 09, 2026
Summary
This early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main goal was to check the safety and tolerability of the combination. Researchers also looked at how well the cancer responded to treatment, such as tumor shrinkage and how long it stayed controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
-
Chiba Cancer Center
Chiba, Chiba, Japan
-
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
-
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
-
Osaka International Cancer Institute
Osaka, Osaka, Japan
-
Saitama Cancer Center
Shinden, Saitama, Japan
-
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan
-
The Cancer Institute Hospital Of JFCR
Koto-ku, Tokyo, Japan
-
Tohoku University Hospital
Sendai, Miyagi, Japan
-
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
-
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.